BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.
The French drugmaker is expanding its neurology activities with the $470m deal.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
